JP2017505787A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017505787A5 JP2017505787A5 JP2016551163A JP2016551163A JP2017505787A5 JP 2017505787 A5 JP2017505787 A5 JP 2017505787A5 JP 2016551163 A JP2016551163 A JP 2016551163A JP 2016551163 A JP2016551163 A JP 2016551163A JP 2017505787 A5 JP2017505787 A5 JP 2017505787A5
- Authority
- JP
- Japan
- Prior art keywords
- och
- nhch
- optionally
- sch
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims description 437
- 150000001875 compounds Chemical class 0.000 claims description 73
- -1 CH 3 Inorganic materials 0.000 claims description 56
- 206010028980 Neoplasm Diseases 0.000 claims description 30
- 201000011510 cancer Diseases 0.000 claims description 30
- 230000000694 effects Effects 0.000 claims description 23
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 8
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 6
- 201000004384 Alopecia Diseases 0.000 claims description 6
- 206010005003 Bladder cancer Diseases 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 206010020112 Hirsutism Diseases 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 6
- 229940123237 Taxane Drugs 0.000 claims description 6
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 6
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 6
- 206010000496 acne Diseases 0.000 claims description 6
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 6
- 208000024963 hair loss Diseases 0.000 claims description 6
- 230000003676 hair loss Effects 0.000 claims description 6
- 208000002780 macular degeneration Diseases 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 208000025661 ovarian cyst Diseases 0.000 claims description 6
- 201000004228 ovarian endometrial cancer Diseases 0.000 claims description 6
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims description 6
- 208000006155 precocious puberty Diseases 0.000 claims description 6
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 6
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 6
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 21
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461940275P | 2014-02-14 | 2014-02-14 | |
| US61/940,275 | 2014-02-14 | ||
| US201462023773P | 2014-07-11 | 2014-07-11 | |
| US62/023,773 | 2014-07-11 | ||
| PCT/CA2015/000086 WO2015120543A1 (en) | 2014-02-14 | 2015-02-13 | Human androgen receptor dna-binding domain (dbd) compounds as therapeutics and methods for their use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019056915A Division JP2019142880A (ja) | 2014-02-14 | 2019-03-25 | 治療薬としてのヒトアンドロゲン受容体ｄｎａ結合ドメイン（ｄｂｄ）化合物およびそれらを使用する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017505787A JP2017505787A (ja) | 2017-02-23 |
| JP2017505787A5 true JP2017505787A5 (enExample) | 2018-03-22 |
Family
ID=53799465
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016551163A Pending JP2017505787A (ja) | 2014-02-14 | 2015-02-13 | 治療薬としてのヒトアンドロゲン受容体ｄｎａ結合ドメイン（ｄｂｄ）化合物およびそれらを使用する方法 |
| JP2019056915A Pending JP2019142880A (ja) | 2014-02-14 | 2019-03-25 | 治療薬としてのヒトアンドロゲン受容体ｄｎａ結合ドメイン（ｄｂｄ）化合物およびそれらを使用する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019056915A Pending JP2019142880A (ja) | 2014-02-14 | 2019-03-25 | 治療薬としてのヒトアンドロゲン受容体ｄｎａ結合ドメイン（ｄｂｄ）化合物およびそれらを使用する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10011573B2 (enExample) |
| EP (1) | EP3105229A4 (enExample) |
| JP (2) | JP2017505787A (enExample) |
| KR (1) | KR20160115999A (enExample) |
| CN (1) | CN106164071B (enExample) |
| AU (1) | AU2015218140A1 (enExample) |
| BR (1) | BR112016018691A2 (enExample) |
| CA (1) | CA2939048A1 (enExample) |
| MX (1) | MX2016010604A (enExample) |
| RU (1) | RU2016136091A (enExample) |
| WO (1) | WO2015120543A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3511319T3 (fi) * | 2014-07-03 | 2023-07-20 | Celgene Quanticel Res Inc | Lysiinispesifisen demetylaasi-1:n inhibiittoreita |
| EP3555091A1 (en) | 2016-12-19 | 2019-10-23 | H. Hoffnabb-La Roche Ag | Ar-v7 inhibitors |
| WO2019023651A2 (en) | 2017-07-28 | 2019-01-31 | Massachusetts Institute Of Technology | MODULATORS OF THE SMALL MOLECULE ANDROGEN RECEPTOR |
| WO2019126739A1 (en) | 2017-12-21 | 2019-06-27 | Shepherd Therapeutics, Inc. | Pyrvinium pamoate anti-cancer therapies |
| CN108003148A (zh) * | 2017-12-22 | 2018-05-08 | 佛山汉方中医医院有限公司 | 异丙基哌嗪噻吩二环腈类化合物、制备方法及其用途 |
| CN108148051A (zh) * | 2017-12-22 | 2018-06-12 | 佛山汉方中医医院有限公司 | 一种含氟噻吩的二环腈类ssao抑制剂及其用途 |
| CN108084171A (zh) * | 2017-12-22 | 2018-05-29 | 佛山汉方中医医院有限公司 | 哌嗪噻吩二环腈类化合物、制备方法及其用途 |
| CN108129469A (zh) * | 2017-12-22 | 2018-06-08 | 佛山汉方中医医院有限公司 | 一种异丙基哌嗪硝基噻吩二环腈类化合物及其用途 |
| CN108084170A (zh) * | 2017-12-22 | 2018-05-29 | 佛山汉方中医医院有限公司 | 一类含哌嗪烷氧噻吩结构的二环腈类化合物、制备方法及其用途 |
| CN108003147A (zh) * | 2017-12-22 | 2018-05-08 | 佛山汉方中医医院有限公司 | 异丙基哌嗪氟噻吩二环腈类化合物、制备方法及其用途 |
| CN108003146A (zh) * | 2017-12-22 | 2018-05-08 | 佛山汉方中医医院有限公司 | 一类含烷氧噻吩的二环腈类ssao抑制剂、制备方法及其用途 |
| CN108047213A (zh) * | 2017-12-22 | 2018-05-18 | 佛山汉方中医医院有限公司 | 一种含硫环的氟噻吩的二环腈类化合物及其用途 |
| CN108084168A (zh) * | 2017-12-22 | 2018-05-29 | 佛山汉方中医医院有限公司 | 一种哌嗪噻吩二环腈类化合物、制备方法及其用途 |
| CN108129470A (zh) * | 2017-12-22 | 2018-06-08 | 佛山汉方中医医院有限公司 | 异丙基哌嗪噻吩二环腈类化合物、其制备方法及其用途 |
| CN108069949A (zh) * | 2017-12-22 | 2018-05-25 | 佛山汉方中医医院有限公司 | 烷基取代的哌嗪甲基噻吩二环腈类化合物、制备方法及其用途 |
| CN108069950A (zh) * | 2017-12-22 | 2018-05-25 | 佛山汉方中医医院有限公司 | 一种含噻吩的二环腈类ssao抑制剂、制备方法及其用途 |
| CN107936002A (zh) * | 2017-12-22 | 2018-04-20 | 佛山汉方中医医院有限公司 | 一种异丙基哌嗪胺基噻吩二环腈类化合物及其用途 |
| CN107880032A (zh) * | 2017-12-22 | 2018-04-06 | 佛山汉方中医医院有限公司 | 含噻吩的二环腈类ssao抑制剂、制备方法及其用途 |
| CN108084169A (zh) * | 2017-12-22 | 2018-05-29 | 佛山汉方中医医院有限公司 | 一种硝基噻吩的二环腈类化合物及其用途 |
| CN108069948A (zh) * | 2017-12-22 | 2018-05-25 | 佛山汉方中医医院有限公司 | 一种ssao抑制剂、其制备方法及其用途 |
| CN108069947A (zh) * | 2017-12-22 | 2018-05-25 | 佛山汉方中医医院有限公司 | 含二甲胺噻吩和异丙基哌嗪胺基结构的二环腈类化合物及用途 |
| US20220106304A1 (en) | 2018-10-03 | 2022-04-07 | The University Of British Columbia | Transcription Factor BRN2 Inhibitory Compounds as Therapeutics and Methods for Their Use |
| EP3917916A4 (en) | 2019-01-30 | 2022-12-14 | Montelino Therapeutics, Inc. | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor |
| US11547759B2 (en) | 2019-01-30 | 2023-01-10 | Montelino Therapeutics, Inc. | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor |
| US11465998B2 (en) | 2019-04-25 | 2022-10-11 | Regents Of The University Of Minnesota | Therapeutic compounds and methods of use thereof |
| CA3150878A1 (en) * | 2019-09-12 | 2021-03-18 | Jonathan Bentley | Inhibitors of sarm1 |
| WO2021236695A1 (en) * | 2020-05-18 | 2021-11-25 | Montelino Therapeutics, Inc. | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor |
| US11981672B2 (en) | 2021-09-13 | 2024-05-14 | Montelino Therapeutics Inc. | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor |
| WO2024059951A1 (en) * | 2022-09-22 | 2024-03-28 | The University Of British Columbia | Inhibitors of the androgen receptor dna-binding domain |
| WO2024102810A1 (en) | 2022-11-08 | 2024-05-16 | Montelino Therapeutics, Inc. | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor |
| CN116768881B (zh) * | 2023-06-30 | 2025-09-09 | 郑州大学 | 4-(3-吲哚基)-1,3-噻唑类化合物及其制备方法和应用 |
| WO2025064918A1 (en) * | 2023-09-20 | 2025-03-27 | The Board Of Regents Of The University Of Texas System | First-in-class phospho-brd4 inhibitors |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3509271A1 (de) * | 1985-03-15 | 1986-09-18 | Basf Ag, 6700 Ludwigshafen | Isothiazol-azofarbstoffe |
| DE3521406A1 (de) * | 1985-06-14 | 1986-12-18 | Bayer Ag, 5090 Leverkusen | 2,2-diaryl-chromenothiazole, ihre herstellung und ihre verwendung in aufzeichnungsmaterialien |
| JPH11209284A (ja) * | 1998-01-27 | 1999-08-03 | Sagami Chem Res Center | 骨形成促進剤 |
| TW583185B (en) * | 2000-06-13 | 2004-04-11 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same |
| US6451814B1 (en) * | 2000-07-17 | 2002-09-17 | Wyeth | Heterocyclic β-3 adrenergic receptor agonists |
| WO2002051821A1 (en) * | 2000-12-22 | 2002-07-04 | Astrazeneca Ab | Therapeutic compounds |
| US6528223B1 (en) * | 2001-11-20 | 2003-03-04 | Nexpress Solutions Llc | Magenta-colored toner particles for electrostatographic imaging |
| EP1478631A1 (en) | 2001-11-28 | 2004-11-24 | AstraZeneca AB | Therapeutic compounds |
| GB0315111D0 (en) * | 2003-06-27 | 2003-07-30 | Cancer Rec Tech Ltd | Substituted 5-membered ring compounds and their use |
| US7384966B2 (en) | 2004-08-31 | 2008-06-10 | Pharminxo Limited | 2-arylbenzothiazole derivatives |
| CN101103007A (zh) * | 2004-11-18 | 2008-01-09 | 武田药品工业株式会社 | 酰胺化合物 |
| GB0503962D0 (en) * | 2005-02-25 | 2005-04-06 | Kudos Pharm Ltd | Compounds |
| CA2599320A1 (en) * | 2005-02-25 | 2006-08-31 | Kudos Pharmaceuticals Limited | Hydrazinomethyl, hydr zonomethyl and 5-membered heterocylic compounds which act as mtor inhibitors and their use as anti cancer agents |
| JP5388574B2 (ja) * | 2005-05-31 | 2014-01-15 | バーテックス ファーマシューティカルズ インコーポレイテッド | イオンチャネルのモジュレーターとして有用なヘテロ環式類 |
| SI2656842T1 (sl) | 2006-03-27 | 2016-10-28 | The Regents Of The University Of California | Modulator androgenih receptorjev za zdravljenje raka prostate in bolezni, povezanih z androgenimi receptorji |
| CA2662359A1 (en) * | 2006-09-21 | 2008-03-27 | Novartis Ag | Pyrrole derivatives useful for the treatment of cytokine-mediated diseases |
| JP5461197B2 (ja) * | 2007-02-02 | 2014-04-02 | ベイラー カレッジ オブ メディスン | 代謝障害を処置するための組成物および方法 |
| US9085566B2 (en) * | 2007-02-02 | 2015-07-21 | Baylor College Of Medicine | Compositions and methods for the treatment of metabolic and related disorders |
| DE102007040243A1 (de) * | 2007-08-25 | 2009-02-26 | Universität des Saarlandes | 17Beta-Hydroxysteriod-Dehydrogenase Typ1 Inhibitoren zur Behandlung hormonabhängiger Erkrankungen |
| ES2491522T3 (es) * | 2008-06-19 | 2014-09-08 | Millennium Pharmaceuticals, Inc. | Derivados de tiofeno o tiazol y su uso como inhibidores de PI3K |
| WO2010118347A2 (en) * | 2009-04-10 | 2010-10-14 | Zacharon Pharmaceuticals, Inc. | O-linked glycan biosynthesis modulators |
| DE102010012594A1 (de) * | 2010-03-23 | 2011-09-29 | Beiersdorf Ag | Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an einem oder mehreren Thiazolderivaten |
| US20130096160A1 (en) * | 2010-04-14 | 2013-04-18 | Secretary, Department Of Health And Human Services | Arylthiazolyl piperidines and related compounds as modulators of survival motor neuron (smn) protein production |
| US8642632B2 (en) * | 2010-07-02 | 2014-02-04 | Radius Health, Inc. | Selective androgen receptor modulators |
| US20140221374A1 (en) * | 2011-03-17 | 2014-08-07 | Ruga Corporation | Raf kinase inhibitors |
| WO2012143599A1 (en) * | 2011-04-21 | 2012-10-26 | Orion Corporation | Androgen receptor modulating carboxamides |
-
2015
- 2015-02-13 BR BR112016018691A patent/BR112016018691A2/pt not_active Application Discontinuation
- 2015-02-13 AU AU2015218140A patent/AU2015218140A1/en not_active Abandoned
- 2015-02-13 JP JP2016551163A patent/JP2017505787A/ja active Pending
- 2015-02-13 US US15/118,652 patent/US10011573B2/en not_active Expired - Fee Related
- 2015-02-13 CA CA2939048A patent/CA2939048A1/en not_active Abandoned
- 2015-02-13 KR KR1020167025134A patent/KR20160115999A/ko not_active Withdrawn
- 2015-02-13 MX MX2016010604A patent/MX2016010604A/es unknown
- 2015-02-13 CN CN201580015292.9A patent/CN106164071B/zh not_active Expired - Fee Related
- 2015-02-13 RU RU2016136091A patent/RU2016136091A/ru unknown
- 2015-02-13 EP EP15748487.4A patent/EP3105229A4/en not_active Withdrawn
- 2015-02-13 WO PCT/CA2015/000086 patent/WO2015120543A1/en not_active Ceased
-
2019
- 2019-03-25 JP JP2019056915A patent/JP2019142880A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017505787A5 (enExample) | ||
| RU2395500C2 (ru) | 2,4-пиримидиндиамины, применяемые в лечении неопластических болезней, воспалительных и иммунных расстройств | |
| MX2021010700A (es) | Compuestos utiles en la terapia del vih. | |
| CN114072396A (zh) | 作为dna-pk抑制剂的喹啉和噌啉衍生物 | |
| CL2024000067A1 (es) | Compuestos antivirales | |
| EP4275748A3 (en) | Compositions and methods for treating cns disorders | |
| PH12015501881A1 (en) | Amide compounds for the treatment of hiv | |
| RU2016136091A (ru) | Соединения, воздействующие на днк-связывающий домен (dbd) андрогенового рецептора человека, в качестве терапевтических средств, а также способы их применения | |
| MY199779A (en) | Pyrrolopyrimidine compound and use thereof | |
| MX2021000941A (es) | Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar canceres que incluyen los mismos. | |
| CY1125285T1 (el) | Θεραπεια για τη νοσο του παρκινσον | |
| TN2018000393A1 (en) | Pegylated carfilzomib compounds | |
| PH12019501690A1 (en) | Pyrimidine compound and pharmaceutical use thereof | |
| PH12020551486A1 (en) | Cyclopentane-based modulators of sting (stimulator of interferon genes) | |
| EP4342473A3 (en) | Compounds useful in hiv therapy | |
| PH12021552513A1 (en) | Pyrrole compounds | |
| MX2021012705A (es) | Compuestos con actividad antitumoral contra las celulas cancerosas que portan mutaciones en el receptor del factor de crecimiento epidermico (egfr) resistentes al inhibidor de la tirosina quinasa. | |
| MX2025010357A (es) | Degradador de irak4, y uso del mismo | |
| NZ758449A (en) | Heteroaromatic compounds useful in therapy | |
| MX382765B (es) | Tratamiento para la colangitis biliar primaria. | |
| PH12017501130A1 (en) | Indenyl compounds, pharmaceutical compositions, and medical uses thereof | |
| PH12020551117A1 (en) | Compositions for preventing or treating uveitis | |
| BR112017007426A2 (pt) | compostos aromáticos substituídos e composições farmacêuticas para prevenir e tratar osteoporose | |
| JOP20220038A1 (ar) | عوامل مضادة للملاريا | |
| PH12021552953A1 (en) | Tricyclic compounds |